[1] |
Yousuf Zafar S, Abernethy AP. Financial toxicity, Part I:a new name for a growing problem[J]. Oncology, 2013, 27(2):80-81,149.
|
[2] |
Patel MR, Zhang GH, Heisler M,et al. Measurement and validation of the comprehensive score for financial toxicity(COST) in a population with diabetes[J]. Diabetes Care, 2022, 45(11):2535-2543.
|
[3] |
Lee YS, Khan AA. Financial toxicity for female patients with urinary incontinence[J]. Curr Urol Rep, 2023, 24(1):33-39.
|
[4] |
Savarese G, Becher PM, Lund LH,et al. Global burden of heart failure:a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023, 118(17):3272-3287.
|
[5] |
2017 Disease and Injury Incidence and Prevalence Collaborators GBD. Global,regional,and national incidence,prevalence,and years lived with disability for 354 diseases and injuries for 195 countries and territories,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159):1789-1858.
|
[6] |
Chan RJ, Gordon LG, Tan CJ,et al. Relationships between financial toxicity and symptom burden in cancer survivors:a systematic review[J]. J Pain Symptom Manage, 2019, 57(3):646-660.e1.
|
[7] |
Ali HR, Javier VE, STEPHEN Y W,et al. Subjective financial hardship due to medical bills among patients with heart failure in the United States:the 2014-2018 medical expenditure panel survey[J]. J Card Fail, 2022, 28(9):1424-1433.
|
[8] |
Bradley CJ, Yabroff KR, Zafar SY,et al. Time to add screening for financial hardship as a quality measure?[J]. CA Cancer J Clin, 2021, 71(2):100-106.
|
[9] |
Altice CK, Banegas MP, Tucker-Seeley RD,et al. Financial hardships experienced by cancer survivors:a systematic review[J]. J Natl Cancer Inst, 2017, 109(2):djw205.
|
[10] |
Heidenreich PA, Bozkurt B, Aguilar D,et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2022, 79(17):e263-e421.
|
[11] |
胡雁, 王志稳. 护理研究[M]. 6版. 北京: 人民卫生出版社, 2022.
|
|
Hu Y, Wang ZW. Nursing research[M]. 6th ed. Beijing: People’s Medical Publishing House, 2022.
|
[12] |
Wang H, Chai K, Du MH,et al. Prevalence and incidence of heart failure among urban patients in China:a national population-based analysis[J]. Circ Heart Fail, 2021, 14(10): e008406.
|
[13] |
Yu Y, Liu K, Zhang LH,et al. Perceived economic burden,mortality,and health status in patients with heart failure[J]. JAMA Netw Open, 2024, 7(3):e241420.
|
[14] |
Slavin SD, Khera R, Yousuf Zafar S, et al. Financial burden,distress,and toxicity in cardiovascular disease[J]. Am Heart J, 2021, 238:75-84.
|
[15] |
Weida EB, Phojanakong P, Patel F,et al. Financial health as a measurable social determinant of health[J]. PLoS One, 2020, 15(5):e0233359.
|
[16] |
López-Baamonde M, Arguis MJ, Navarro-Ripoll R,et al. Multimodal prehabilitation in heart transplant recipients improves short-term post-transplant outcomes without increasing costs[J]. J Clin Med, 2023, 12(11):3724.
|
[17] |
Greenup RA. Financial toxicity and shared decision making in oncology[J]. Surg Oncol Clin N Am, 2022, 31(1):1-7.
doi: 10.1016/j.soc.2021.08.001
pmid: 34776059
|
[18] |
Members WC, Members AJC. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail,2022, 28(5):e1-e167.
|
[19] |
Cleland JFG, Clark RA. Telehealth:delivering high-quality care for heart failure[J]. Lancet, 2018, 392(10152):990-991.
doi: S0140-6736(18)31995-0
pmid: 30153986
|
[20] |
Sydow H, Prescher S, Koehler F,et al. Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure:health economic analysis of the TIM-HF2 trial[J]. Clin Res Cardiol, 2022, 111(11):1231-1244.
|